Planning Grant: Pharmacokinetics and tolerability of adjunctive linezolid for the treatment of tuberculous meningitis
The following grant was awarded by, is supported by, is administered by or is in partnership with the Fogarty International Center at the U.S. National Institutes of Health (NIH).
Funding Fogarty Program
Global Brain Disorders Research
Project Information in NIH RePORTER
Pharmacokinetics and tolerability of adjunctive linezolid for the treatment of tuberculous meningitis
Principal Institution
University of California San Francisco
Principal Investigator(s) (PI)
Chow, Felicia C
Project Contact Information
Email: felicia.chow@ucsf.edu
Year(s) Awarded
2018-2023
Country
Uganda
Collaborators
Regents of the University of Minnesota
Infectious Diseases Institute, Makerere University
Project Description
Tuberculous meningitis (TBM) is a devastating form of tuberculosis (TB) with high rates of death and neurologic disability, particularly in individuals living with HIV infection. This open label randomized controlled trial will evaluate the pharmarcokinetics and tolerability of a 4-week course of adjunctive linezolid administered with high and standard dose rifampin early in the treatment of TBM in adults living with HIV in Uganda, which has a large burden of HIV/TB co-infection. The knowledge gained from this trial will be used to determine an optimal linezolid dose for a future efficacy trial of adjunctive linezolid to improve clinical outcomes in TBM.
Related World Regions / Countries
Related Global Health Research Topics